Afatinib Maleate Tablets (Lishunfu®) – 40?mg Wholesale price comparison
$1.00
Afatinib maleate (Lishunfu®) is a potent oral irreversible pan-ErbB tyrosine kinase inhibitor targeting EGFR/HER2/HER4, approved in China (NMPA No.?H20233920, Code?86900647000282), manufactured by Shanghai Chuannuo Pharma. Supplied as 40?mg tablets (7 tablets per box; barcode: 6973850270142). Intended strictly for laboratory research use only—?Please consult the staff for other purposes?
.
描述
Afatinib Maleate Tablets Product Specifications
| Attribute | Details |
|---|---|
| Product Name | Afatinib Maleate Tablets (Lishunfu®) |
| Strength | 40?mg per tablet |
| Quantity | 7 tablets per box |
| Formulation | Oral film-coated tablet |
| Approval No. | China NMPA H20233920 |
| Product Code | 86900647000282 |
| Barcode | 6973850270142 |
| Manufacturer | Shanghai Chuannuo Pharmaceutical Co., Ltd. |
| Intended Use | Laboratory research use only — Not for human or veterinary use |
Mechanism of Action
Afatinib is an irreversible pan-ErbB family inhibitor, forming covalent bonds at the ATP-binding sites of EGFR (ErbB1), HER2 (ErbB2), and HER4. It effectively suppresses signaling pathways in EGFR-mutant NSCLC cells resistant to first-generation TKIs.
Research & Reference Background
-
Clinically approved for EGFR-mutant NSCLC, including exon?19 deletions, L858R, and those harboring T790M following 1st-gen TKI failure .
-
Demonstrated superior progression-free survival over gefitinib in pivotal trials—making it a tool compound in EGFR resistance research.
-
Widely used in in vitro signaling pathway, resistance mechanism, and drug combination studies targeting the ErbB network.
Research Applications
-
EGFR signaling across mutated NSCLC models
-
Resistance pathway exploration—e.g., HER2/HER3 compensatory signaling
-
Drug combination studies involving EGFR inhibitors and chemotherapeutics
-
Pharmacokinetic/dynamics profiling of irreversible TKIs
?? Research?Use Disclaimer
This product is provided strictly for laboratory research and development use only. Not intended for human, veterinary, clinical, diagnostic, or therapeutic applications.
其他信息
| 重量 | 1.1 公斤 |
|---|---|
| 尺寸 | 18 × 16 × 18 厘米 |
相关产品
-
Toremifene Citrate Tablets (Ovry®) – 60?mg
Toremifene citrate (brand name Ovry®), manufactured by Jiangsu Ascend Pharmaceutical Co., Ltd., is a selective estrogen receptor modulator (SERM) approved in China (NMPA No.?H20243050, code?86901425001187). Each box contains 30 tablets (60?mg each) in 3 blister cards (barcode?6953272600284). Strictly for laboratory research purposes only. $1.00 -
Elranatamab Injection 76?mg/1.9?mL/Freeze-dried powder
Elranatamab (ELREXFIO®) is a BCMA-CD3 bispecific antibody used in multiple myeloma research. Supplied as a 76?mg/1.9?mL single-dose vial, manufactured by Pfizer. Approved by FDA (Aug?2023) and EMA (Dec?2023). Ideal for oncology, immunotherapy, and T?cell engager studies.
$1.00
?? For laboratory research use only – Not for human consumption or therapeutic use. -
Temozolomide Capsules 100?mg × 5 – ChuanNuo (MySean) | Research Grade Glioblastoma Drug
Temozolomide 100?mg capsules, 5?count box, produced by Shanghai ChuanNuo Pharmaceuticals Co., Ltd., approved under NMPA H20234716. A key alkylating agent for glioblastoma and astrocytoma research—ideal for preclinical oncology models.
?? For laboratory research or analytical use only – Not for human consumption or therapeutic use. $1.00 -
Pirtobrutinib Tablets (Jaypirca) – 100?mg × 14 Tablets × 4 Blisters Price comparison
Pirtobrutinib Tablets (brand name: Jaypirca) is the world’s first non-covalent BTK inhibitor, provided here as 100?mg oral film?coated tablets. Manufactured by Lilly del Caribe, Inc. and approved for import in China (NMPA No. HJ20240116; code 86978403001613). Supplied with clear indication for research/investigational use only, not for human therapeutic use. $2.00
评价
目前还没有评价